Put companies on watchlist
HBM Healthcare Investments AG
ISIN: CH0012627250
WKN: 984345
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

HBM Healthcare Investments AG · ISIN: CH0012627250 · EQS - adhoc news (170 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1999967
01 October 2024 05:46PM

HBM Healthcare Investments posts half-year profit of CHF 23 million for 2024/2025 financial year; currency effects had a strong negative impact on the result


HBM Healthcare Investments AG / Key word(s): Half Year Results
HBM Healthcare Investments posts half-year profit of CHF 23 million for 2024/2025 financial year; currency effects had a strong negative impact on the result

01-Oct-2024 / 17:46 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


HBM Healthcare Investments achieved a positive performance in the first half of the 2024/2025 financial year. The net asset value per share (NAV) increased by 1.5 per cent to CHF 244.34. The share price rose by 1.7 per cent to CHF 189.40.

Based on the reported NAV, the company expects a half-year profit of around CHF 23 million (previous year: loss of CHF 70 million).

Private companies (sale of Yellow Jersey Therapeutics to Johnson & Johnson, revaluation of Swixx Biopharma and impairment losses on various investments) and listed companies contributed equally to the increase in value. Negative currency effects reduced performance by just under 5 per cent.

These figures are the preliminary result based on the current state of the closing process. The final result will be published with the half-year report on 21 October 2024.

Contact
For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com.



End of Inside Information
Language: English
Company: HBM Healthcare Investments AG
Bundesplatz 1
6300 Zug
Switzerland
Phone: +41438887171
Fax: +41438887172
E-mail: info@hbmhealthcare.com
Internet: https://www.hbmhealthcare.com
ISIN: CH0012627250
Valor: 1262725
Listed: SIX Swiss Exchange
EQS News ID: 1999967

 
End of Announcement EQS News Service

1999967  01-Oct-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1999967&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - HBM Healthcare Investments AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.